Background: Overuse, the provision of health services for which harms outweigh the benefits, results in suboptimal patient care and may contribute to the rising costs of cancer care. We performed a systematic review of the evidence on overuse in oncology.
D espite a stable cancer incidence, the cost of cancer care is high and is rising more rapidly than costs in other medical sectors; in the United States, the estimated total cost of cancer care was 125 billion US$ in 2010 and is projected to increase to 173 billion US$ by 2020. 1 These escalating costs have led to concerns about the ability of the health care system to pay 2 and have led to removal of some drugs from coverage in the United Kingdom. 3 In the United States, rising costs are also relevant to individual patients who are experiencing rising deductibles, increased cost shifting, and growing premiums. 1, 4 As a result, there is a growing emphasis on improving value in cancer management. 5, 6 One approach to improving value in cancer care is the identification and elimination of overuse.
In health care, overuse can be defined as the provision of medical care that has no benefit or for which harms outweigh potential benefits. 7 In 2012, the Institute of Medicine estimated that in the United States >750 billion US$ a year, or nearly 30% of all medical expenses, resulted from unnecessary or inefficient services, contributing to thousands of unexpected deaths. 8 In response, there has been a call to action by national organizations to identify and eliminate overuse. In 2012, attention to overuse accelerated with the launch of the Choosing Wisely campaign from the ABIM Foundation, in which specialty societies identified services that patients and clinicians should question and reconsider. 9 The American Society of Clinical Oncology (ASCO) was an early supporter of Choosing Wisely. 10, 11 Although there has been increased recognition by ASCO and others of the importance of reducing overuse to improve the value of cancer care, the scope of overuse in oncology has not been well described. A 2012 systemic review of overuse of all health care services in the United States included papers published from 1978 to 2011 and found few addressed overuse in cancer. 12 However, it is likely that additional studies have been undertaken in more recent years given the greater attention to overuse and value. 13, 14 To describe the current prevalence of overuse in cancer care and the state of the overuse literature in cancer, we performed a systematic review of published articles reporting rates of overuse of diagnostic tests, therapeutic procedures, and medications in the management of patients diagnosed with cancer. We chose to focus on patients with a cancer diagnosis and not on cancer screening as cancer care itself is particularly costly and overuse of screening has been well discussed in the literature. [15] [16] [17] [18] [19] 
METHODS

Literature Search
This systematic review was conducted according to PRISMA guidelines. 20 We conducted systematic literature searches in 5 databases for references written in all languages with no specified sex or ages, limited to human-only research, and published from December 1, 2011 to March 10, 2017. We used controlled vocabulary and text words to search (1) MEDLINE (via PubMed), (2) EMBASE, ( 3) The Cochrane Library, (4) Web of Science, and (5) Scopus. The Web of Science and Scopus databases do not use controlled vocabularies, so they were searched using only text words. We also conducted comprehensive searches in 2 grey literature sources: (a) Grey Literature Report provided by the New York Academy of Medicine; and (b) Open Grey which is operated by the Institute of Scientific and Technical Information (INIST-CNRS) in Vandoeuvre-les-Nancy, France.
The search strategy included 2 major components that were linked together with the AND operator: (1) cancer terms including neoplasms, tumors, carcinomas, sarcomas, and malignancies; (2) health services overuse terms including laboratory testing, imaging, secondary screening/testing, overutilization, choosing wisely, overuse, and guideline adherence (see Fig., Supplementary Digital Content 1, http:// links.lww.com/MLR/B376 for a complete list of MeSH and keyword terms used). After combining the concepts in all 5 databases, we added the following publication type filters to the search (where applicable): clinical trial, comparative study, controlled clinical trial, observational study, pragmatic clinical trial, review, systematic review, meta-analysis, technical report, and guidelines. We performed reference tracking by searching the references of all studies included for full-text review.
Study Selection
Each title and abstract was reviewed by 1 of 4 investigators (D.K., M.K., S.K., A.Y.) to determine inclusion for full-text review. Each full-text article, including those identified through reference tracking, was reviewed by a pair of investigators (D.K. and B.R.R., D.K. and M.K., S.S.B. and D.K., or S.S.B. and M.K.) to determine inclusion for qualitative synthesis. Disagreements were resolved by group consensus. We determined interrater reliability (Cohen k) for each of the 4 pairs of full-text reviewers. The flow of article selection is presented in Figure 1 .
Articles were eligible for inclusion if they were original research quantifying overuse of any medical service in patients with a cancer diagnosis and utilizing an acceptable standard that included: (1) a guideline from a governmental organization; (2) a guideline from a professional society; (3) a multidisciplinary panel consensus process (eg, Rand appropriateness method); or (4) a Choosing Wisely recommendation. We excluded studies in patients without cancer including those evaluating cancer screening in the general population, and studies in which overuse rates were not presented or calculable.
Data Extraction
We developed a data extraction tool to collect information from each study in the review. Data extraction was performed by 1 reviewer (S.S.B., D.K., M.K., B.R.R.) and checked by a second reviewer (S.S.B. or D.K.) for accuracy. The following data were extracted from each study: general information about the publication (first author's name, year of publication), study specifics (eg, study design, data source, and sample size), cancers addressed, country of study, type of service (eg, diagnostic vs. therapeutic), and where in the cancer continuum the service was provided. We categorized the cancer care continuum as diagnostic evaluation, active treatment, surveillance after active treatment, or end of life. We recorded specific service(s) evaluated, whether costs were reported with overuse and whether an intervention to reduce overuse was evaluated. We also noted whether overuse was presented as the percent of the population receiving a nonrecommended service or as the percent of services provided inappropriately. We documented overuse of each individual service separately. When rates of overuse were not directly presented we calculated rates when possible and contacted study authors for rates of overuse or raw data when we were unable to calculate with information reported.
We assessed the quality of each study by assessing for potential bias in design. In all studies, we evaluated for bias in patient selection (eg, 1 physician's panel) and in the determination of the appropriateness of the service (eg, determinations of appropriateness were subjective and nonreproducible). We categorized studies that used only claimsbased data as having potential bias because the lack of detailed clinical information could lead investigators to incorrectly classify the appropriateness of particular services.
Data Analysis
Given the diversity of the literature, we did not believe that quantitative analysis was scientifically justified and conducted only qualitative data analysis. Interrater reliability for the decision to include the article in the review (Cohen k, 0.85, 0.66, 0.84, 0.82 for the 4 investigator pairs) was excellent.
We generated descriptive statistics to analyze studies included in the systematic review. We synthesized information for all services that were evaluated for overuse. We recorded overuse of either an aggregate of multiple services in a specific situation (eg, any inappropriate surveillance imaging in breast cancer patients) and/or of an individual service [eg, positron emission tomography (PET) scan for surveillance in breast cancer patients] based on how the data were presented in the original article. We defined an individual service as a distinct test or treatment in a defined population based on the disease, specific test or treatment [ 
RESULTS
Study Characteristics
Our primary search identified 13,064 articles, of which 59 met our inclusion criteria (Fig. 1) . Characteristics of included studies are summarized in Table 1 and details of all studies are listed in Table 2 . All studies were published in English, most were retrospective (92%), were completed in the United States (76%), and addressed overuse in adult or geriatric cancer patients (98%). The National Cancer Institute's linked Surveillance, Epidemiology, and End Results (SEER)-Medicare was the most commonly analyzed dataset, used in 37% of all studies; 14 studies (24%) were framed around a Choosing Wisely item. In terms of quality, 41 (69%) of studies had some form of bias, mostly due to use of claims-based data. Three studies (5%) evaluated an intervention to address overuse and 9 (15%) addressed financial costs associated with overuse (Table 2) .
Clinical Services Studied
Because many included studies reported overuse rates for multiple services, the 59 included studies assessed the overuse of 154 distinct services. The most common cancers addressed were breast (49% of services) and prostate (32% of services) ( Table 3 ). In terms of phase of cancer care, studies were predominantly focused on diagnostic evaluation (56%) followed by posttreatment surveillance (23%), active treatment (19%), and end of life (1%). The most commonly evaluated service modality was imaging (71%) with a fair representation of numerous imaging modalities.
Multiple addressed services related to the overuse of imaging in early-stage breast and prostate cancer. Overuse of imaging in the diagnostic evaluation of early prostate cancer was addressed 43 times with 20 (47%) of these evaluations relying on SEER-Medicare data. Similarly, 34 of the evaluated services related to diagnostic imaging for staging in early-stage breast cancer, with 8 (24%) relying on SEERMedicare data, most commonly assessing overuse of PET (n = 7), CT (n = 7), bone scan (n = 7), or any advanced imaging (n = 3). Overuse of radiographic surveillance following treatment for early-stage breast cancer was also commonly addressed (n = 22 evaluations).
Rates of Overuse
The majority of studies (n = 53, 90%) reported overuse as a percentage of the population receiving a nonrecommended service and many (n = 27, 46%) used administrative data to determine the prevalence of overuse. Three studies compared rates of overuse measured from administrative data to measurements for the same service using clinical data. 40, 41, 65 Studies of high-tech imaging at the time of diagnosis in earlystage breast cancer found that administrative data overreported clinically relevant imaging as overuse (prevalence 15% vs. 8% from clinical data). 40 In a second study, rates of overuse of posttreatment imaging for surveillance in early-stage breast cancer were higher using administrative data from 8618 patients compared with chart review from a subset of 110 patients from the larger dataset. The rates differed widely for CT (20% vs. 0.8%) and PET or bone scan (4.3% vs. 0.8%). Interestingly, rates of overuse of tumor markers were similar from both data sources (28% vs. 28%). 41 The third study reported higher measured rates of overuse of radioactive iodine for low-risk thyroid from administrative (range, 47%-53%) Vazin 79 : liver function test in breast surveillance: 62% (n = 564); MRI in breast surveillance: 12% (n = 928); chest x-ray in breast surveillance: 25% (n = 928); chest CT in breast surveillance: 8% (n = 928); PET in breast surveillance: 1% (n = 928); hormonal therapy in breast: 74% (n = 375); chemotherapy, postmenopausal breast patients: 36% (n = 346); chemotherapy, premenopausal breast: 55% (n = 266); diagnostic PET in stage III breast: 17% (n = 598); diagnostic PET in stage I-II breast: 4% (n = 6827); diagnostic brain imaging in breast: 2% (n = 6827); radiation in breast: 4% (n = 965); diagnostic brain imaging in lung: 37% (n = 1437); systemic therapy in lung: 40%
(n = 147); growth factors in non-Hodgkin lymphoma: 23% (n = 232). AT indicates active treatment; CEA, carcinoembryonic antigen; CRC, colorectal; CT, computerized tomography; D, diagnostic; EOL, end of life; H&N, head and neck; HCC, hepatocellular carcinoma; IMRT, intensitymodulated radiation therapy; MRI, magnetic resonance imaging; NCDB, National Cancer Database; NHL, non-Hodgkin lymphoma; P, prospective; PET, positron emission tomography; R, retrospective; S, surveillance. (6) versus clinical (range, 20%-32%) data (note that Table 2 reflects rates determined through administrative review). 65 Rates of overuse varied widely between 0% and 100% across services ( Table 2 ). The most frequently studied services were bone scan (n = 17 evaluations) and CT (n = 11 evaluations) for staging of low and/or intermediate-risk prostate cancer and tumor markers for surveillance in early-stage breast cancer (n = 9 evaluations); rates of overuse were 0.09%-100%, 5%-72%, and 5%-77%, respectively, across studies. Overuse of cancer-directed pharmacologic agents, including chemotherapy, targeted, and hormonal therapies was measured in lung, breast, and prostate cancer. Weeks and colleagues found that rates of overuse of chemotherapy were B40% in patients with metastatic lung cancer and a poor performance status, 36% in postmenopausal women with limited metastatic breast cancer, and 55% in premenopausal women with limited metastatic breast cancer. 79 In the adjuvant setting, a study in rural Georgia reported 11.5% of women received overtreatment with hormonal therapy. 36 Targeted therapy was addressed in 2 studies evaluating the appropriate use of trastuzumab, the monoclonal antibody directed at the human epidermal receptor 2 (HER2). Overuse of trastuzumab was reported in 3.9% and 4.7% of patients due to a lack of documentation of HER2 testing. 37, 73 Three studies evaluated the overuse of antiandrogen therapy in low-risk prostate cancer where it is not routinely recommended, 67, 72, 77 demonstrating a decline in rates of overuse over time 72 and high levels of geographic variation across the United States. 77 Outside the United States, a French study reported that B21% of all chemotherapy administered for any cancer at 2 academic centers was administered against national guideline recommendations. 47 
Interventional Studies
We identified 3 studies evaluating interventions; all aimed to reduce overuse of imaging in patients with newly diagnosed low-risk and intermediate-risk prostate cancer. In 1 study, Miller and colleagues evaluated guideline dissemination followed by utilization review and feedback through the Urological Surgery Quality Collaborative. They reported decreased rates of bone scans and CT scans from 31% to 21% and 28% to 13% (P < 0.01), respectively. 54 In a Swedish study, Makarov and colleagues reported decline in inappropriate diagnostic imaging over a 10-year period from 45% to 3% (P < 0.001) in patients with low-risk prostate cancer after national guideline dissemination. This appropriate decline was accompanied by a simultaneous unwanted decline in recommended imaging in high-risk patients from 63% to 47% (P < 0.001). 51 In the more recent MUSIC study, Ross and colleagues reported the results of a state-wide collaboration in Michigan to reduce diagnostic imaging in patients with lowrisk prostate cancer. Rates of overuse of bone scans (3.7%) and CT scans (5.2%) were low at the start of the study and declined to 1.3% (P = 0.03) and 3.2% (P = 0.17), respectively. 64 
DISCUSSION
Our review of overuse in cancer care delivery identified 59 articles published over the last 6 years evaluating 154 clinical services. The majority of studies focused on overuse of imaging in early-stage breast cancer and low to intermediaterisk prostate cancer, and despite concerns about the high cost of active cancer care only 29% of studies addressed services delivered during active treatment. 2 Rates of overuse varied widely among studies and among services addressed. Despite calls to reduce overuse, very few studies evaluated interventions and costs associated with overuse were rarely reported.
Overuse of Imaging
There were multiple studies addressing imaging in breast and prostate cancers. However, the prevalence of overuse of these services remains difficult to define with rates of overuse of specific tests varying widely (though overuse of PET was consistently uncommon). Further, even in this well-studied clinical area, estimates of cost associated with overuse were rare. Despite this lack of clarity on the extent of the problem of overuse of diagnostic imaging in early prostate cancer, all 3 interventional studies in our review addressed methods to reduce it. Those interventions were generally successful, but the clinical and financial implications of that success are not clear and in 1 study, reductions in overuse were accompanied by unwanted reduction in recommended services.
Overuse of Systemic Therapy
Data are still lacking on some of the most concerning, and costly, areas of overuse in cancer. Although new highcost, cancer-directed therapies represent a significant driver of rising oncology care costs, 14, 80 few studies evaluated rates of overuse of cancer treatments, which can lead to financial harm even when used appropriately. We identified 2 studies evaluating overuse of newer, high-cost drugs, both of which focused on trastuzumab for patients with HER2-positive breast cancer; both reported relatively low rates of use in the absence of appropriate HER2 testing. 37, 73 The remaining therapeutic studies evaluated chemotherapies more generically, but did not specifically address high-cost therapeutics.
Methodology of Overuse Research
Our review highlights important issues related to the research of overuse and informs possible strategies aimed at reducing inappropriate health care utilization in cancer patients. First, overuse can only be measured when a normative practice has been established. By definition, identifying overuse implies that there are established criteria for appropriate use of a service, available as a guideline or other standard. In cancer and many other diseases, there may be lack of consensus on optimal management in many clinical situations, so appropriate use cannot be determined. It may be that we identified numerous studies addressing imaging in early-stage prostate and breast cancer because these were the services highlighted by the ASCO Choosing Wisely campaign in 2012. Further, studies of services for which appropriateness is more nuanced, such as chemotherapy use in patients with metastatic solid tumors and poor performance status, are challenging and therefore less likely to be performed, even if those services may be more important in terms of patient outcomes and cost.
In addition, even when appropriate care can be defined, its measurement can be difficult without detailed clinical information that often requires chart review. So while overuse is measurable in these situations, it is infrequently evaluated because doing so is time consuming and cumbersome. As a result, much of the cancer overuse literature focuses on issues where there are both clear recommendations and the opportunity to measure use through administrative datasets such as SEER-Medicare, mainly evaluating diagnostic imaging in early-stage cancers and for posttreatment surveillance. Indeed, many (49%) studies we identified presented data from administrative datasets and over half (64%) of the services studied represented diagnostic and/or surveillance imaging. Overrepresentation of imaging and overreliance on claims data for overuse research may bias both the topics of study and estimates of rates of overuse. Despite widespread concern about overuse at the end of life, 81, 82 we found only 1 study addressing overuse in this setting, likely because of the challenges of assessing appropriateness of this care. In addition, in the 3 studies we identified that used both clinical and administrative data to assess overuse, overuse rates derived from clinical data were much lower for most services than those identified through administrative data, suggesting that much of the literature may be overestimating the prevalence of overuse of imaging. 40, 41, 65 However, clinically documented indications in support of imaging might represent clinician efforts to secure imaging reimbursement in situations in which the clinician favors routine imaging; thus chart review may underestimate overuse. This phenomenon may be specific to evaluations of imaging, either because it requires insurance authorization or because it is done for a variety of clinical indications. 41 True rates of overuse of nonrecommended imaging likely lie between the high rates derived from administrative data and the low rates derived from chart review.
Going forward, it will be critical both to focus inquiry on the areas of greatest clinical and/or financial importance and to generate reliable estimates of overuse informed by detailed clinical data. Priority areas for research will need to be defined, with participation from stakeholders including government, professional societies and patients, focusing on services with the most potential to harm patients or the health system. Choosing Wisely has become somewhat of a focal point since 2012, with 14 (24%) of included studies mentioning it. However, the emphasis in our study sample on relatively few clinical services suggests that we need to go further. Researchers must find creative ways to accurately measure overuse across populations while minimizing bias. Cancer cooperative groups that conduct clinical trials may provide opportunities to use relevant prospectively collected clinical data to measure overuse rates while enabling evaluations of interventions to reduce overuse.
Limitations
Our study has a number of limitations. First, standard MeSH terminology for overuse in MEDLINE was only introduced in 2016, so identifying articles reporting rates of overuse is challenging and we may have missed some. We addressed this by performing extensive reference tracking and by searching multiple databases, so it is unlikely we missed major publications. We excluded articles without a generally accepted standard for defining overuse. Although this approach may have excluded some less rigorous but thematically relevant articles, our study provides an estimate of rates of true overuse to inform our understanding of the literature on overuse in cancer care delivery.
CONCLUSIONS
Despite recognition of the need to improve value in cancer care and the importance of avoiding overuse, our systematic review suggests gaps in our understanding of overuse in patients with cancer. Although we found many studies evaluating diagnostic or surveillance imaging in breast and prostate cancer, there is a dearth of data on overuse in other clinical scenarios, particularly overuse of cancer therapeutics and at the end of life, and an emphasis on using administrative data. Given the enormity of the cost and potential harm associated with overuse in cancer care, there is a need to identify priority areas for investigation to expand the evidence base and inform future efforts to reduce overuse.
